Jamie L. March

Jamie L. March

Auto-generated profile, based on publicly available information

Jamie L. March

Health Economics and Market Access, Biosense Webster, Inc., Diamond Bar, CA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2012 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
SHSteven C. Hao
Steven C. Hao
THTina D. Hunter
Tina D. Hunter
CGCandace Gunnarsson
Candace Gunnarsson
JMJamie L. March
Jamie L. March
SWSarah A. White
Sarah A. White
MRMatthew R. Reynolds
Matthew R. Reynolds

1 May 2017 in Pragmatic and Observational Research
Verified
Journal Article
Open access
PDF file
JJJulian We Jarman
Julian We Jarman
THTina D Hunter
Tina D Hunter
WHWajid Hussain
Wajid Hussain
JMJamie L March
Jamie L March
TWTom Wong
Tom Wong
VMVias Markides
Vias Markides
Background: We sought to determine from key clinical outcomes whether catheter ablation of atrial fibrillation (AF) is associated with increased survival. Methods and results: Using routinely collected hospital data, ablation patients were matched to two control cohorts using direct and propensity score methodology. Four thousand nine hundred ninety-one ablation patients were matched 1:1 with general AF controls without ablation. Five thousand four hundred seven ablation patients were similarly matched to controls who underwent cardioversion. We examined the rates of ischemic stroke or transient ischemic attack (stroke/TIA), heart failure hospitalization, and death. Matched populations had very similar comorbidity profiles, including nearly identical CHA2DS2-VASc risk distribution (p=0.6948 and p=0.8152 vs general AF and cardioversion cohorts). Kaplan–Meier models showed increased survival after ablation for all outcomes compared with both control cohorts (p<0.0001 for all outcomes vs general AF, p=0.0087 for stroke/TIA, p<0.0001 for heart failure, and p<0.0001 for death vs cardioversion). Cox regression models also showed improved survival after ablation for all outcomes compared with the general AF cohort (hazard ratio [HR]=0.4, 95% confidence interval [95% CI]: 0.3–0.6, p<0.0001 for stroke/TIA; HR=0.4, 95% CI: 0.2–0.6, p<0.0001 for heart failure; HR=0.1, 95% CI: 0.1–0.1, p<0.0001 for death) and the cardioversion cohort (HR=0.6 , 95% CI: 0.4–0.9, p=0.0111 for stroke/TIA; HR=0.4, 95% CI: 0.3–0.6, p<0.0001 for heart failure; HR=0.3, 95% CI:0.2–0.5, p<0.0001 for death). Conclusions: Catheter ablation of AF was associated with very significant reductions in mortality, stroke/TIA, and heart failure compared with a matched general AF population and a matched population who underwent cardioversion. Potential confounding of outcomes was minimized by very tight cohort matching.

1 May 2017 in Pragmatic and Observational Research
Verified
Journal Article
Open access
PDF file
JJJulian We Jarman
Julian We Jarman
THTina D Hunter
Tina D Hunter
WHWajid Hussain
Wajid Hussain
JMJamie L March
Jamie L March
TWTom Wong
Tom Wong
VMVias Markides
Vias Markides
Background: We sought to determine whether catheter ablation of atrial fibrillation (AF) is associated with reduced occurrence of ischemic cerebrovascular events. Methods and results: Using routinely collected hospital data, ablation patients were matched to two control cohorts via direct and propensity score matching. A total of 4,991 ablation patients were matched 1:1 to general AF controls with no ablation, and 5,407 ablation patients were similarly matched to controls who underwent cardioversion. Yearly rates of ischemic stroke or transient ischemic attack (stroke/TIA) before and after an index date were compared between cohorts. Index date was defined as the first ablation, the first cardioversion, or the second AF event in the general AF cohort. Matched populations had very similar demographic and comorbidity profiles, including nearly identical CHA2DS2-VASc risk distribution (p-values 0.6948 and 0.8152 vs general AF and cardioversion cohorts). Statistical models of stroke/TIA risk in the preindex period showed no difference in annual event rates between cohorts (mean±standard error 0.30% ± 0.08% ablation vs 0.28% ± 0.07% general AF, p=0.8292; 0.37% ± 0.09% ablation vs 0.42% ± 0.08% cardioversion, p=0.5198). Postindex models showed significantly lower annual rates of stroke/TIA in ablation patients compared with each control group over 5 years (0.64% ± 0.11% ablation vs 1.84% ± 0.23% general AF, p<0.0001; 0.82% ± 0.15% ablation vs 1.37% ± 0.18% cardioversion, p=0.0222). Conclusion: Matching resulted in cohorts having the same baseline risks and rates of ischemic cerebrovascular events. After the index date, there were significantly lower yearly event rates in the ablation cohort. These results suggest the divergence in outcome rates stems from variance in the treatment pathways beginning at the index date.